How BMI and cholesterol affect AML treatment outcomes
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how your body weight (BMI) and blood fat levels (cholesterol and triglycerides) might affect how well treatment works for adults with newly diagnosed acute myeloid leukemia (AML). It could help doctors better understand factors that influence recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have just been diagnosed with acute myeloid leukemia (AML) that is not a relapse or caused by another condition.
- Your doctor plans to treat you with strong chemotherapy right away.
- You do not take any medicine to lower your cholesterol (like statins).
- You do not have uncontrolled diabetes, an underactive thyroid, or Cushing's syndrome.
- You are not pregnant or breastfeeding and are willing to follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how a simple blood test (CRP to Albumin ratio) relates to blood clotting problems in people newly diagnosed with Acute Myeloid Leukemia (AML). The goal is to better understand how the disease affects your body and find ways to monitor your health.
This study is looking at a substance called leptin in the blood of people with newly diagnosed acute myeloid leukemia (AML). The goal is to see if leptin levels can help doctors predict how well chemotherapy will work, which could guide better treatment choices.
This study looks at how blood counts and clotting change in adults newly diagnosed with acute myeloid leukemia (AML) who receive a strong type of chemotherapy. It aims to better understand how to manage these patients during treatment.
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
Hear when a new BMI trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.